Infliximab 5 mg/kg and purine analogues vs purine analogues: Clinical response as defined by the studies at week 26
Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Infliximab 5 mg/kg and purine analogues vs purine analogues alone Clinical response as defined by the studies at week 26 · active Crohn's disease Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty). Infliximab for medical induction of remission in Crohn's disease (2023) · Cochrane Headline outcomes only | RR 1.64 [1.31, 2.05] | 2 studies · 355 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.